Curated News
By: NewsRamp Editorial Staff
July 28, 2026
Greenland Mines Secures Canadian Patent for Klotho Gene Therapy
TLDR
- Greenland Mines' Canadian patent strengthens its IP for Klotho gene therapies, potentially giving it a competitive edge in neurological disease treatments.
- The patent covers 42 claims for s-KL RNA splice variant synthesis, delivery, and application in Alzheimer's, Parkinson's, ALS, and multiple sclerosis.
- Klotho gene therapies aim to combat neurodegenerative diseases, offering hope for improved cognition and memory, making tomorrow better for patients.
- Greenland Mines, known for mining, now advances gene therapy for brain diseases, with KLTO-202 entering GMP manufacturing for ALS treatment.
Impact - Why it Matters
This patent strengthens Greenland Mines' position in the growing field of gene therapies for neurodegenerative diseases, potentially accelerating development of treatments for conditions like Alzheimer's and ALS. For investors, it signals expanded IP protection and a clearer path to clinical milestones. For patients, it offers hope for new therapies targeting memory and cognition.
Summary
Greenland Mines (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. Greenland Mines is a Nasdaq-listed company with two operating divisions: Mining, focused on the Skaergaard Project and the Sarfartoq rare earths project, and Biotech, including Klotho’s KLTO‑202 primary indication for ALS. The company’s strategy is centered on building a multi-asset platform with exposure to rare earth magnet materials, precious metals and selected midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Greenland Mines Secures Canadian Patent for Klotho Gene Therapy
